A menin inhibitor for certain acute leukaemias
Revumenib
A specialist targeted medicine used to treat certain acute leukaemias with particular genetic changes.
What is Revumenib?
Revumenib is a specialist targeted cancer medicine, a 'menin inhibitor', used to treat certain acute leukaemias driven by particular genetic changes (involving the KMT2A or NPM1 genes). It works by interrupting a process the leukaemia cells rely on, encouraging them to mature and stop multiplying. Two important risks needing close monitoring are differentiation syndrome (a reaction as leukaemia cells mature, causing fever, breathing problems and fluid build-up) and lengthening of the heart's electrical rhythm (the QT interval). It is given only by a specialist cancer team.
Education and reference only. This is a plain-language guide to Revumenib — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Revumenib is a targeted cancer medicine used to treat some types of acute leukaemia (a cancer of the blood and bone marrow) that are driven by specific genetic changes, particularly rearrangements of the KMT2A gene or mutations of the NPM1 gene. It is a 'menin inhibitor', a newer kind of targeted treatment that blocks a protein interaction the leukaemia cells depend on. It is taken by mouth, but it is very much a specialist medicine, given and closely monitored by a hospital cancer team because of the careful monitoring it needs.
How it works
In these particular leukaemias, the cancer cells rely on a protein called menin working together with other proteins to keep the cells in an immature, fast-dividing state. Revumenib blocks this menin interaction, which releases the cells from that state and encourages them to mature normally and stop multiplying. As the leukaemia cells mature, large numbers can be affected at once, which is the basis of differentiation syndrome, a reaction the team watches for closely. The treatment is used under specialist care with regular blood tests and heart monitoring.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist targeted cancer medicine used to treat certain acute leukaemias with particular genetic changes (KMT2A or NPM1).
Practical use
How to take Revumenib
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Take it by mouth exactly as your cancer team directs, as part of a carefully monitored treatment plan.
- Report straight away any fever, breathlessness, rapid weight gain or swelling, which can be signs of differentiation syndrome.
- Attend all appointments for blood tests and heart tracings (ECGs), as close monitoring is essential.
- Give your team a full list of your medicines, as revumenib interacts with several of them.
- Tell your team about any heart-rhythm problems or fainting spells before and during treatment.
Weighing it up
Advantages & disadvantages of Revumenib
Advantages
- Targets the specific genetic driver of certain acute leukaemias rather than acting broadly.
- Taken by mouth as part of a specialist treatment plan.
- Offers a treatment option for leukaemias that can be difficult to treat.
Disadvantages
- Can cause differentiation syndrome, a potentially serious reaction needing prompt treatment.
- Can lengthen the heart's electrical rhythm (the QT interval), needing regular ECGs.
- Requires intensive specialist monitoring and interacts with several other medicines.
Practical use
Good to know
Two safety points dominate treatment with revumenib and are the reason for very close monitoring. The first is differentiation syndrome, a reaction that can happen as the leukaemia cells mature, causing fever, breathlessness, a fast weight gain or swelling from fluid build-up, and a drop in blood pressure; it can be serious, so any of these symptoms must be reported straight away, and the team can treat it. The second is that revumenib can lengthen the heart's electrical rhythm (the QT interval), so electrocardiograms (ECGs) and blood salt levels are checked regularly. Because it acts on the blood and bone marrow, blood counts and infection risk are also monitored. It is a hospital-supervised specialist treatment, and it interacts with several other medicines, so a full medicines list is essential.
Who should not take it / use with caution
- People who have had a serious allergic reaction to revumenib should not take it.
- It is used with particular caution in people with heart-rhythm problems or a long QT interval.
- It should only be used under a specialist hospital cancer team, with close monitoring.
Monitoring
- Watching closely for differentiation syndrome, especially early in treatment.
- Regular electrocardiograms (ECGs) and checks of blood salt levels for the heart's rhythm.
- Regular blood counts to watch for low cells, infection and bleeding risk.
Side effects
- Differentiation syndrome, with fever, breathlessness, fluid build-up and low blood pressure, which needs prompt treatment.
- Changes in the heart's electrical rhythm (the QT interval).
- Nausea, tiredness, low blood counts and a raised risk of infection or bleeding.
Key interactions
- Medicines that also affect the heart's QT interval can add to the risk and are reviewed.
- Several medicines change how revumenib is broken down, so the dose may need adjusting.
- Give a full list of your medicines, including herbal products, as many can interact.
Available as: Tablets taken by mouth, under specialist supervision.
Answers
Revumenib: frequently asked questions
What is revumenib used for?
It is a targeted medicine used to treat certain acute leukaemias driven by specific genetic changes (involving the KMT2A or NPM1 genes), by blocking a protein the cancer cells rely on.
What is differentiation syndrome?
It is a reaction that can happen as the leukaemia cells mature, causing fever, breathlessness, fluid build-up and low blood pressure; it can be serious, so report these symptoms straight away.
Does it affect the heart?
It can lengthen the heart's electrical rhythm (the QT interval), so your team checks ECGs and blood salt levels regularly during treatment.
Is it a chemotherapy?
It is a targeted therapy (a menin inhibitor) rather than traditional chemotherapy; it blocks the specific process the leukaemia cells depend on.
Why does my team need my full medicines list?
Revumenib interacts with several other medicines, some affecting the heart rhythm and some changing its levels, so a complete list helps keep treatment safe.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.